Question explored with the scientific record
How does atorvostatin impact on the relative risk for amyotrophic lateral sclerosis?
The short version: the only direct evidence on statins and ALS comes from a mouse study, and it shows harm, not benefit.
The one study that actually tested this question is a 2016 experiment in SOD1 G93A mice, a standard ALS model [7]. Mice given simvastatin (2 mg/kg/day) died significantly faster than controls. Median survival dropped from 143 days to 132 days. The hazard ratio for death was 1.97, meaning the statin nearly doubled the risk of dying at any given time [7]. The effect was consistent across two genetic backgrounds. Coenzyme Q10 did not rescue the animals [7].
No human study on atorvastatin and ALS risk was retrieved. The evidence base for this question is essentially a single animal experiment. That experiment found a clear signal of harm. The mechanism is plausible: statins block the mevalonate pathway, which produces coenzyme Q10 and other molecules needed for mitochondrial function and cell survival. ALS involves mitochondrial dysfunction and oxidative stress [2]. A drug that impairs those systems in a disease defined by them is a bad fit.
The retrieved studies on respiratory training, botulinum toxin for drooling, and isothiocyanates from broccoli are about managing ALS symptoms, not about whether a drug causes or prevents the disease [1, 3, 4, 5, 6]. They do not answer the question.
My call: the evidence, thin as it is, points toward atorvastatin increasing ALS risk, not lowering it. The mouse data shows accelerated death. No human data exists to override that signal. Confidence: low, because the evidence is limited to one animal model, but the direction of harm is consistent and mechanistically coherent.
Sources used 7
-
Respiratory training improved ventilatory function and respiratory muscle strength in patients with multiple sclerosis and lateral amyotrophic sclerosis: systematic review and meta-analysis
This systematic review and meta-analysis found that respiratory muscle training significantly improves ventilatory function and respiratory muscle strength in patients with multiple sclerosis and amyotrophic lateral sclerosis, although it does not significantly affect forced vit…
DOI: 10.1016/j.physio.2016.01.002 -
Mitochondrial Proteomic Analysis of a Cell Line Model of Familial Amyotrophic Lateral Sclerosis
This study employs proteomic approaches to identify mitochondrial proteins altered by the G93A-SOD1 mutant in a cell line model of familial amyotrophic lateral sclerosis (fALS), revealing significant changes in protein abundance and post-translational modifications that may cont…
DOI: 10.1074/mcp.m400094-mcp200 -
An overview on neuroprotective effects of isothiocyanates for the treatment of neurodegenerative diseases
This 2015 review surveys evidence that isothiocyanates (ITCs) derived from glucosinolates in Brassicaceae and Moringaceae exert neuroprotective effects in diverse in vitro and in vivo models of neurodegenerative diseases by activating the Nrf2/ARE antioxidant pathway, reducing i…
DOI: 10.1016/j.fitote.2015.08.001 -
Diaphragm Training in Amyotrophic Lateral Sclerosis
This pilot study investigated the effects of diaphragm training on respiratory function and quality of life in patients with amyotrophic lateral sclerosis, finding no significant improvements in the measured outcomes despite some trends suggesting potential benefits for those wh…
DOI: 10.1097/CND.0b013e31818cf6df -
Respiratory training in an individual with amyotrophic lateral sclerosis
This study investigates the effects of expiratory muscle strength training on respiratory function in a 71-year-old male with amyotrophic lateral sclerosis, demonstrating significant improvements in maximum expiratory pressure and cough spirometry after training.
DOI: 10.1002/acn3.342 -
Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review
This study reviews the efficacy of botulinum toxin as an alternative treatment for sialorrhea in patients with amyotrophic lateral sclerosis, highlighting its positive outcomes and minimal side effects.
DOI: 10.1590/S1679-45082016RB3594 -
Statins accelerate disease progression and shorten survival in SOD1 G93A mice
In a mouse model of ALS (SOD1 G93A) statin treatment accelerates disease progression and shortens survival, with the H67D HFE genotype modulating this effect; coenzyme Q10 does not rescue outcomes, and ferritin elevations correlate with disease status, while mitochondrial protei…
DOI: 10.1002/mus.25048